Recent news on Human Erythropoietin

3SBio Inc. Announces First Quarter 2007 Results  -  May 1, 2007
PR Newswire (press release),Net revenue from our flagship injectable recombinant human erythropoietin ("EPO") products, marketed under our EPIAO brand, increased 12.7% over the first

Kirin's NESP(R) Long-Acting Erythropoiesis Stimulating Agent ...  -  26 Apr 2007
Japan Corporate News (press release),NESP(R) is manufactured by partially modifying the amino acid sequence of human erythropoietin (EPO) and attaching new sugar chains.

New Human Cell-Produced Treatment for Anaemia Associated With ...  -  Mar 28, 2007
Drug Newswire (press release),This is accomplished by activating the endogenous human erythropoietin gene in a human cell line using specialised gene-activating DNA sequences.

Billion dollar babies—biotech drugs as blockbusters  -  Apr 3, 2007
Nature.com (subscription),...like industry mainstay erythropoietin (Epogen or Procrit recombinant human erythropoietin, marketed by Amgen of Thousand Oaks, California,

DNAPrint(TM) Genomics` Advancements in PT-401 and Statinome ...  -  Apr 5, 2007
MacReport (press release),In one study, PT-401 was shown to be more potent and longer acting than epoetin alfa, a form of recombinant human erythropoietin currently in the market for

3SBio Inc. Announces Fourth Quarter And Fiscal Year 2006 Results  -  Apr 2, 2007
MSN MoneyNet revenue from our flagship injectable recombinant human erythropoietin products, or EPO products, marketed under our EPIAO brand, increased 28.8% over

New Human Cell-Produced Treatment for Anaemia Associated With ...  -  Mar 16, 2007
PR Newswire UK (press release),This is accomplished by activating the endogenous human erythropoietin gene in a human cell line using specialised gene-activating DNA sequences.

New Human Cell-Produced Treatment for Anaemia Associated With ...  -  Mar 15, 2007
Earthtimes.orgThis is accomplished byactivating the endogenous human erythropoietin gene in a human cell lineusing specialised gene-activating DNA sequences.

The Protein Engineering Market is Forecasted to Rise to $118 ...  -  Mar 14, 2007
PharmaLive.com (press release),...therapeutic protein is Amgen's Aranesp, a re-engineered variant of the company's first-generation product, Epogen (recombinant human erythropoietin).

Shire undercuts rivals with launch of Dynepo drug  -  Mar 15, 2007
Reuters.uk,Dynepo is the first "fully human" erythropoietin (EPO), produced in human cell lines rather than animal ones. Rival EPO drugs already available in Germany,

Biotechnology and the Divine Right of Kings  -  Mar 15, 2007
Agoravox,If memory serves me correctly, Amgen’s original patent on recombinant human erythropoietin was issued in 1984. That was 23 years ago!

Care conflict over BC sextuplets sparks  -  Mar 9, 2007
National Review of Medicine,What's more, the substitute therapies favoured by the church, such as recombinant human erythropoietin, are usually poorly suited to neonatal treatment.

Addition of Browne and Chiu Strengthens ITC and Asia Practice ...  -  Feb 27, 2007
Lawfuel (press release),26 battery manufacturers) and the Recombinant Human Erythropoietin investigation (Amgen v. Roche). A number of the clients she has represented before the

Purification of Biologically Active Human Erythropoietin-Binding ...  -  Feb 20, 2007
Annals of Clinical & Laboratory Science (subscription),To purify human erythropoietin-binding protein (Epo-bp), the recombinant vector JYL26 was constructed by inserting human Epo-receptor cDNA by PCR into a

BioLineRx Prices $50M IPO, Listing On Tel Aviv Exchange  -  Feb 7, 2007
BioWorld Online,The company, based in Shenyang, China, sells Epiao, an injectable recombinant human erythropoietin for anemia, and Tpiao, a recombinant thrombopoetin for

3SBio IPO on Tap for Next Week  -  Feb 2, 2007
Forbes,The company's lead product is an injectable anemia treatment called EPIAO which uses recombinant human erythropoietin, or EPO, to stimulate the production

Treatment of Anemia in Chronic Kidney Disease  -  Dec 26, 2006
Medscape (subscription)...[4] In 1983, the gene for human erythropoietin was identified, and in 1985, clinical trials were initiated to evaluate the efficacy and safety of

Handler used own urine to pass dog's drug test  -  Dec 23, 2006
The Sunday Times,The samples were being checked by testers at the National Greyhound Laboratory for artificial human erythropoietin (EPO), the blood-doping agent used by

Treatment of Anemia in Chronic Kidney Disease  -  26 Dec 2006
Medscape (subscription)...[4] In 1983, the gene for human erythropoietin was identified, and in 1985, clinical trials were initiated to evaluate the efficacy and safety of

Handler used own urine to pass dog's drug test  -  Dec 23, 2006
The Sunday Times,The samples were being checked by testers at the National Greyhound Laboratory for artificial human erythropoietin (EPO), the blood-doping agent used by

Erythropoietin May Improve Immune Function of Patients with ...  -  Dec 4, 2006
Cancer Consultants (press release),Researchers from Israel have reported that the administration of recombinant human erythropoietin (EPO, Procrit®) improves a variety of immunologic

DNAPrint Pharmaceuticals / Harvard Study Shows PT-401 to Be Three ...  -  Dec 8, 2006
Market Wire (press release)The study's purpose was to determine whether it was possible to develop a more effective erythropoiesis stimulating agent (ESA) than human erythropoietin

United States Anti-Doping Agency  -  Nov 28, 2006
SFCPressPoint (press release),...accepted a two-year period of ineligibility after her sample was reported positive for the prohibited substance recombinant human erythropoietin (EPO).

Sekunjalo Investments Ltd - Audited results for the year ended  -  Nov 27, 2006
Finance24,...in addition to the intellectual property, in the worlds largest biotechnology product- recombinant human erythropoietin (EPO), (Repotin is the Bioclones

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional